OSE Immunotherapeutics SA
PAR:OSE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
OSE Immunotherapeutics SA
Other Items
OSE Immunotherapeutics SA
Other Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
OSE Immunotherapeutics SA
PAR:OSE
|
Other Items
€38.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
72%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Other Items
€2.8m
|
CAGR 3-Years
118%
|
CAGR 5-Years
84%
|
CAGR 10-Years
N/A
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Other Items
-€211k
|
CAGR 3-Years
83%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
N/A
|
|
|
Inventiva SA
PAR:IVA
|
Other Items
-€24.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-24%
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Other Items
-$832k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-52%
|
CAGR 10-Years
0%
|
|
|
Abivax SA
PAR:ABVX
|
Other Items
€16.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
119%
|
CAGR 10-Years
112%
|
|
OSE Immunotherapeutics SA
Glance View
OSE Immunotherapeutics SA develops immunotherapy products for cancer and auto-immune disease. The company is headquartered in Nantes, Pays De La Loire and currently employs 61 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.
See Also
What is OSE Immunotherapeutics SA's Other Items?
Other Items
38.4m
EUR
Based on the financial report for Jun 30, 2025, OSE Immunotherapeutics SA's Other Items amounts to 38.4m EUR.
What is OSE Immunotherapeutics SA's Other Items growth rate?
Other Items CAGR 5Y
72%
